THE EFFECT OF HYDROCORTISONE ON OUTCOME AMONG PATIENTS WITH SEPTIC SHOCK IN INTENSIVE CARE UNIT WITH LARGE VOLUME THORACENTESIS

OM NAEEM; A ULLAH; S BATOOL; RS SAGAR; OA NAEEM; HFU ISLAM

doi:10.54112/bcsrj.v2023i1.553

Authors

OM NAEEM Department of Pulmonology (Head of Dept.), Pak Red Crescent Medical College & Teaching Hospital, Lahore, Pakistan
A ULLAH Department of Physiology, Swat Medical College, KPK, Pakistan.
S BATOOL PIMS, Islamabad, Pakistan.
RS SAGAR Taluka Hospital Khipro, Pakistan
OA NAEEM Naeem Medical Complex, Lahore, Pakistan
HFU ISLAM Department of Anesthesia & ICU, Services Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.553

Keywords:

Hydrocortisone, Septic shock, mortality, ICU

Abstract

This study aimed to determine the effect of hydrocortisone on the outcome of patients with septic shock in the intensive care unit (ICU). A case-control study was conducted at the Pulmonology Department of Pak Red Crescent Medical College & Teaching Hospital, Lahore, from November 2022 to April 2023 on 200 patients presenting with septic shock to the ICU. The patients were divided into two groups: cases (who received hydrocortisone) and controls (who received standard septic shock therapy). Mortality, vasopressor-free days, and mean ICU stay were assessed between groups. The mean age of the patients in the study was 43.55±14.08 years. The mortality rate was significantly lower in the cases group compared to the control group. In the cases group, the mean ICU stay was 8.14±0.817 days, while in the control group, it was 8.97±0.77 days (P = 0.001). In the cases group, the patients had significantly longer vasopressor-free days (9.95±0.82 days); in the control group, it was 8.97±0.85 days (P = 0.0001). The use of hydrocortisone can significantly reduce the ICU stay as well as the need for vasopressors in septic shock patients. The study also found that it has a significant reduction in mortality.

Downloads

Download data is not yet available.

References

Annane, D., Sébille, V., Charpentier, C., Bollaert, P.-E., François, B., Korach, J.-M., Capellier, G., Cohen, Y., Azoulay, E., and Troché, G. (2002). Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. Jama 288, 862-871.

Bone, R. C., Fisher Jr, C. J., Clemmer, T. P., Slotman, G. J., Metz, C. A., Balk, R. A., and Group, M. S. S. S. (1987). A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine 317, 653-658.

Cecconi, M., Evans, L., Levy, M., and Rhodes, A. (2018). Sepsis and septic shock. The Lancet 392, 75-87.

Hussein, A. A., Sabry, N. A., Abdalla, M. S., and Farid, S. F. (2021). A prospective, randomised clinical study comparing triple therapy regimen to hydrocortisone monotherapy in reducing mortality in septic shock patients. International Journal of Clinical Practice 75, e14376.

Polat, G., Ugan, R. A., Cadirci, E., and Halici, Z. (2017). Sepsis and septic shock: current treatment strategies and new approaches. The Eurasian journal of medicine 49, 53.

Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., and Nunnally, M. E. (2017). Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive care medicine 43, 304-377.

Rochwerg, B., Oczkowski, S. J., Siemieniuk, R. A., Agoritsas, T., Belley-Cote, E., D’Aragon, F., Duan, E., English, S., Gossack-Keenan, K., and Alghuroba, M. (2018). Corticosteroids in sepsis: an updated systematic review and meta-analysis. Critical care medicine 46, 1411-1420.

Rothrock, S. G., Cassidy, D. D., Barneck, M., Schinkel, M., Guetschow, B., Myburgh, C., Nguyen, L., Earwood, R., Nanayakkara, P. W., and Panday, R. S. N. (2020). Outcome of immediate versus early antibiotics in severe sepsis and septic shock: a systematic review and meta-analysis. Annals of Emergency Medicine 76, 427-441.

Sherwin, R., Winters, M. E., Vilke, G. M., and Wardi, G. (2017). Does early and appropriate antibiotic administration improve mortality in emergency department patients with severe sepsis or septic shock? The Journal of emergency medicine 53, 588-595.

Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., and Forst, H. (2008). Hydrocortisone therapy for patients with septic shock. New England Journal of Medicine 358, 111-124.

Sterling, S. A., Puskarich, M. A., Glass, A. F., Guirgis, F., and Jones, A. E. (2017). The impact of the Sepsis-3 septic shock definition on previously defined septic shock patients. Critical care medicine 45, 1436.

Suffredini, A. F. (2018). A role for hydrocortisone therapy in septic shock? , Vol. 378, pp. 860-861. Mass Medical Soc.

Thompson, K., Venkatesh, B., and Finfer, S. (2019). Sepsis and septic shock: current approaches to management. Internal Medicine Journal 49, 160-170.

Venkatesh, B., Finfer, S., Cohen, J., Rajbhandari, D., Arabi, Y., Bellomo, R., Billot, L., Correa, M., Glass, P., and Harward, M. (2018). Adjunctive glucocorticoid therapy in patients with septic shock. New England Journal of Medicine 378, 797-808.